Results
The NHANES data projected that 15.9% of US adults slept for 5 or fewer hours per night, 23.8% slept for 6 hours, 27.1% slept for 7 hours, 26.3% slept for 8 hours, and 7.0% slept for 9 or more hours. In descriptive analyses (Table 1) , certain variables (eg, diabetes, hypertension, blood levels of glucose and triglycerides, education, and socioeconomic status) had a U-or inverse U-shaped association with sleep duration, whereas other variables (eg, body mass index, waist circumference) showed a linear relationship, with progressively shorter sleep duration associated with poor outcomes. Serum ALT activities belonged in the latter group (P for trend < .001).
In multivariable analyses, shorter sleep duration had a progressively higher odds of abnormal ALT level. For example, compared with the reference group with sleep duration of 9 or more hours, subjects with a sleep duration of 5 or fewer hours were 35% more likely to have an abnormal ALT level. In contrast, sleep quality showed no association. In sensitivity analyses incorporating insulin resistance and fasting triglyceride levels, using different ALT cut-off values, or incorporating serum C-reactive protein levels, the effects of sleep duration on ALT level remained unchanged. Finally, sleep duration was associated significantly with NAFLD as defined by the US fatty liver index: adults who slept 5 or fewer hours had a 45% higher odds of having NAFLD compared with those who slept 9 or more hours (P for trend ¼ .001).
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Abbreviations used in this paper: ALT, alanine aminotransferase; NAFLD, nonalcoholic fatty liver disease; NHANES, National Health and Nutrition Examination Survey. 1 Based on these data, we estimate 32 million sleep-deprived Americans have abnormal ALT levels and 28.6 million have NAFLD. Because we excluded major etiologies of chronic liver disease, abnormal ALT levels seen in these data likely are linked to NAFLD. Despite limitations related to missing data, we believe this is a robust, US population-based analysis about sleep health and NAFLD. Prior studies, including a recent metaanalysis, reported inconsistent or nonsignificant associations. 5 These associations may be driven by obesity-related insulin resistance and proinflammatory milieu associated with poor sleep. 6, 7 In addition, sleep NOTE. There were 1654 subjects with missing data who were excluded from the analysis. Excluded subjects were similar in age, sex, and smoking status to those included. However, they were more likely to be non-white, less well educated, single, and poor compared with those in the analysis. NAFLD is defined by the US fatty liver index, which is calculated as follows: (e -0.8073
Analyses for fasting glucose, triglyceride, and insulin concentrations for the US fatty liver index and for insulin resistance were limited to 8419 participants who were examined after an overnight fast of a minimum of 8 hours. CI, confidence interval; CRP, C-reactive protein; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; OR, odds ratio. deprivation has been hypothesized to disrupt the hypothalamic-pituitary-adrenal axis, which may contribute to NAFLD. 8 However, it also is possible that sleep duration has an independent association with serum ALT level in subjects with or without NAFLD or other chronic liver disease. For example, some of the metabolic abnormalities commonly associated with NAFLD have a U-shaped relation with sleep (ie, longer-duration sleep being unhealthy), whereas the relationship between sleep duration and ALT level was linear. The association between long sleep duration and metabolic disorders may represent residual confounding or reverse causation, highlighting the limitation of this observational study; firm causal relationships may not be inferred and prospective interventional studies are needed to confirm the association. 2 In summary, optimal sleep duration (!7 h) is associated with a lower likelihood of abnormal ALT levels and NAFLD, independent of metabolic risk factors. Improving sleep health may provide a novel opportunity for intervention in patients with abnormal ALT levels and/or NAFLD.
